Vlad Ratziu - Podcast Details

Shows

EASL Video PodcastsEASL Studio Podcast: JHEP Live: JHEP at 40: What to Expect Next?This episode celebrates 40 years of the Journal of Hepatology, EASL’s flagship journal. Tune in to discover how far we’ve come—and what’s next for the journal. Moderator: Thomas Berg Faculty: Paolo Angeli, Annalisa Berzigotti, Rajiv Jalan, Vlad Ratziu, Frank Tacke and Jessica Zucman-Rossi All EASL Studio Podcasts are available on EASL Campus. Click here to see all EASL Video Podcasts on Apple Podcasts. 2025-04-101h 02

EASL PodcastsEASL Studio Podcast: JHEP Live: JHEP at 40: What to Expect Next?This episode celebrates 40 years of the Journal of Hepatology, EASL’s flagship journal.Tune in to discover how far we’ve come—and what’s next for the journal.Moderator: Thomas Berg Faculty: Paolo Angeli, Annalisa Berzigotti, Rajiv Jalan, Vlad Ratziu, Frank Tacke and Jessica Zucman-RossiAll EASL Studio Podcasts are available on EASL Campus.Click here to see all EASL Video Podcasts on Apple Podcasts.2025-04-031h 02

Medicine Matters: The Springer Medicine PodcastEpisode 13: Advances in MASLD and MASHWelcoming a new name and a new treatment Metabolic dysfunction-associated liver disease is a significant healthcare concern and burden. Until recently there was no approved pharmacologic treatment for the more serious form of the disease, metabolic dysfunction-associated steatohepatitis. In this wide-ranging conversation, Prof. Vlad Ratziu explains the rationale behind the recently updated subclassification and nomenclature for steatotic liver disease, puts the therapeutic advance of resmetirom into context, and looks to the future for MASLD and MASH.2024-08-1437 min

Surfing the MASH TsunamiS5 - E20.3 - Drug Development Highlights From EASL Congress 2024: "Twin-cretins" and efruxiferminNaim Alkhouri and Mazen Noureddin join Jörn Schattenberg and Roger Green to discuss issues regarding incretin agonists and results from the efruxiermin late-breaker at the EASL Congress 2024. Naim shares his general excitement about glucagon agents in general. He mentions that the efinopegdutide study included a semaglutide cell, which showed further reduction in liver fat vs. the GLP-1 agent. Jörn comments on the high level of tolerability in the survodutide trials. Mazen shares his high hopes for GLP/glucagons and the triple agents. He goes back to review the survodutide data from the NEJM ar...2024-06-2214 min

EASL PodcastsEASL Studio Podcast: Arrivederci Milano, hallo Amsterdam!Arrivederci Milano, hallo Amsterdam!FacultyAleksander Krag (Moderator)Debbie Shawcross (Moderator)Cyrielle Caussy (Faculty)Ana Lleo (Faculty)Francesco Negro (Faculty)Vlad Ratziu (Faculty)Virginia Hernández-Gea (Faculty)All EASL Studio Podcasts are available on EASL Campus.2024-06-1223 min

EASL PodcastsEASL Studio Podcast: JHEP Live: The new nomenclature for SLD: A multidisciplinary evaluation and approachIn this episode, the discussants examines the following questions, raised after a Journal of Hepatology’s nomenclature article:Is the introduction of metabolic risk factors (MRF) for the definition of MASLD justified?What are the main issues regarding the measurement and thresholds for MRFs?Is the introduction of the MetALD category clinically justified?Is it necessary to worry about MRFs in a patient drinking increased or excessive amounts of alcohol and if yes, how should these be accounted for in disease classification systems?FacultyVlad Ratziu (Moderator)Giulio Marchesini (Faculty)Nancy Reau (Faculty)Roberto Ve...2023-10-0531 min

EASL PodcastsEASL Studio Podcast: JHEP Live: New and promising drugs for NASH on the horizonNon-alcoholic steatohepatitis (NASH) is rapidly emerging as a leading cause of chronic liver disease, presenting significant challenge due to the limited treatment options available.This EASL Studio JHEP Live aims to explore novel and promising treatments currently being evaluated for the treatment of NASH. In particular:ARO-HSD, an HSD17β13 inhibitor.PXL065 under evaluation in the DESTINY-1 trial.The investigation of an FXR agonist in fibrotic NASH as part of the LIVIFY trial.FacultyProf. Vlad Ratziu (Moderator)Prof. Stephen Harrison (Faculty)Dr Rohit Loomba (Faculty)Dr Loey Lung-Yi Mak (Faculty)R...2023-06-0833 min

Surfing the MASH TsunamiS4-E3.2 - NASH-TAG Review: NITs, Clinical Trial Design and Addressing “Indeterminate Zones”NASH-TAG 2023 proved to be a watershed moment for Fatty Liver disease as exciting drug development readouts, powerful academic work on non-invasive tests and the willingness to dive into the toughest questions aligned in Deer Valley, Utah. In this weekend’s conversation series, Surfing NASH reviews its diverse coverage of the conference by showcasing key excerpts across six recordings with various KOLs, patient advocates and stakeholders.This conversation featuring Stephen Harrison, Mazen Noureddin and Jörn Schattenberg begins with Mazen describing how exciting and informative the new sessions on non-invasive tests were. Specifically, he details his own surprise at...2023-01-1418 min

EASL PodcastsEASL Studio Podcast: JHEP Live: Covid vaccination and associated autoimmune hepatitis Several recent reports have postulated a link between autoimmune hepatitis (AIH) following SARS-CoV-2 infection or vaccination. This EASL Studio JHEP Live discuss the potential links between COVID-19 and AIH.FacultyProf. Vlad Ratziu (Moderator)Prof. Naga Chalasani (Moderator)Prof. Fernando Bril (Faculty)Prof. Robert Fontana (Faculty)Dr Johannes Hartl (Faculty)ℹ️ More information on the topic can be found in these articles:Autoimmune hepatitis and COVID-19: No increased risk for AIH after vaccination but reduced care, Rüther et al., J Hepatol. 2022 Jul; 77(1): 250–251SARS-CoV-2 vaccination can elicit a CD8 T-cell dominant hepatitis, Böttler et al...2022-09-0943 min

Surfing the MASH TsunamiS3-E40.5 - From the Vault: Why Cirrhosis Matters In Clinical Trial StrategyEpisode 40 focuses on lean NASH, and Michelle Long notes that many patients with lean NASH are diagnosed in the Emergency Department when they present with symptoms of decompensating cirrhosis. This conversation from November 2021 considers cirrhotic patients from a different perspective: their uniquely valuable role in clinical trial strategy as the world evolves beyond biopsy as gold standard.Mazen Noureddin notes during this week's episode that when he identifies lean NASH patients, he encourages them strongly to participate in clinical trials. This conversation also looks at the value of cirrhosis studies in clinical trial design, although from a...2022-08-1454 min

Surfing the MASH TsunamiS3-E4.2 - NASH-TAG 2022 Wrap-up: The Fireside Chat and the Changing Paradigm For NASH DiagnosticsLast weekend's NASH-TAG 2022 was the best attended event in the conference's six-year history, and probably the one that will have the greatest long-term impact on diagnosis, treatment and monitoring of Fatty Liver patients. In this wrap-up conversation, our seven-person panel (including two Pharma execs and one diagnostics entrepreneur) discusses reactions to the closing conference session: two one-hour "fireside chats" exploring the potential to improve clinical endpoints for non-cirrhotis Advanced NASH and NASH cirrhosis clinical trials.This conversation focuses on the two "fireside chats" that served both as climax and denouement to NASH-TAG 2022. The first fireside chat started...2022-01-1512 min

Surfing the MASH TsunamiS3-E3 - NASH-TAG 2022 Day Two: Weight loss, Innovative Approaches and the Fireside Chat on Testing MethodsSurfingNASH is covering each day of NASH-TAG 2022. This episode is a "morning after" conversation with Stephen Harrison, Louise Campbell and Jörn Schattenberg reviewing key points of the Day Two discussions, with particular focus on the two "fireside chats" that wrapped up the program.Day Two of NASH-TAG included presentations of new data on wet markers, imaging and combination therapy, discussion of novel targets and advances in our understanding of basic science. All this led up to the meeting's climax + denouement: David Shapiro's talk on why the current trial and approval system is unsustainable and places unnecessary b...2022-01-0950 min

Surfing the MASH TsunamiS2-E63.3 - SurfingNASH's 2021 NAFLD year-in-review Covers NASH Cost Effectiveness and Quality-of-LifeThis conversation is part of SurfingNASH's 2021 NAFLD Year-In-Review. Professor Jörn Schattenberg of the University of Mainz joins Louise Campbell and Roger Green to discuss research and insights regarding NASH cost effectiveness studies and related issues of quality of life.Jörn Schattenberg begins our discussion simply by reviewing some of the year's highlights. His "proof of momentum" statement is unique and dead-on at the same time: Fatty Liver topics were addressed in three New ENgland Journal of Medicine articles this year despite not having a new drug approval. When discussing the Liver International paper on...2021-12-3035 min

Surfing the MASH TsunamiS2-E63 - Manal Abdelmalek, Ken Cusi And Jörn Schattenberg Join SurfingNASH's 2021 NAFLD Year-In-ReviewThe last half of December marks our annual NAFLD Year-in-Review. Episodes 62-64 each include ~20 minute segments of longer interviews with Stakeholders who have made a dent in Fatty Liver disease in 2021. In this episode, Louise Campbell and Roger Green are joined by Manal Abdelmalek, Kenneth Cusi and Jörn Schattenberg.Highlights:3:26 – Manal Abdelmalek introduction and discussion: opportunities in the new drug pipeline and ways to treat using older agents until new agent arrive5:06 – Manal: urgent to treat cirrhosis when it appears. Reversal may not be “achievable;” but blunting progression can provide stability 9:51 – We learn more...2021-12-271h 02

Surfing the MASH TsunamiS2-E58.1 - Focus On NASH Cirrhosis: Why Cirrhosis Matters and Review of REVERSE Results at AASLDThis episode follows S2 E43 in discussing the possible role of NASH cirrhosis clinical trials in the transition from biopsy as gold standard to a post-biopsy world. Stephen Harrison starts this conversation by discussing why we focus on NASH cirrhosis and goes on to review the recent presentation of results from the REVERSE study on obeticholic acid. Jörn Schattenberg and Mazen Noureddin add their perspectives to the conversation.In this conversation, Stephen starts by pointing out that non-cirrhotic NASH trials and NASH cirrhosis trials differ significantly in goals, endpoints and patient severity. From there, h...2021-11-2714 min

Clinical Liver Disease17-6: Obeticholic Acid for the Treatment of Nonalcoholic SteatohepatitisAudible Article by Vlad Ratziu 2021-10-0909 min

Surfing the MASH TsunamiS2-E35 - #ILC2021 Day Four - Promising Times Ahead, Maybe With a Few More Bumps In the RoadDonna Cryer, Vlad Ratziu, Michael Charlton and Mazen Noureddin join Roger Green in reviewing the final day of #ILC 2021.The conversation revolved around three themes: non-invasive tests as presented at the morning LITMUS session; two promising but incomplete drug trials for a new class of agents and a possible therapy for controlled cirrhotics, and the opportunities and challenges presented by digital meetings (with kudos to EASL for all the platform elements they strengthened from 2020).2021-06-261h 13

Dialogues on AI Digital PathologySpecial Episode (PART 4) - Conversation with KOL Hepatologists and Pharma Thought Leaders in NASHWe’re very happy to bring you Part 4 that will wrap up the Special Episode podcast of Dialogues on AI Digital Pathology! In this Part 4 podcast, our guests – KOL Hepatologists and Pharma Thought Leaders in NASH – continue their discussions in response to questions by Pharma companies and clinical investigators. Find out their views on how AI Digital Pathology (AI-DP) can effectively impact NASH drug development, preclinical studies and clinical practice with granular histopathological data. Please click here to view the Key Takeaways for Part 4 or go to https://tinyurl.com/b4ttvb4s. ...2021-06-0749 min

Dialogues on AI Digital Pathology[Official Trailer] Special Episode (PART 4) - Conversation with KOL Hepatologists and Pharma Thought Leaders in NASHDialogues on AI Digital Pathology is releasing Part 4 of its Special Episode real soon! Listen to this trailer for a snippet of Part 4 with our guests, KOL hepatologists and Pharma Thought Leaders in NASH, as they continue their discussions on AI Digital Pathology (AI-DP), and the application and future of AI-DP in clinical practice, liver research, and drug development. Guests Prof. Stephen Harrison, Medical Director, Pinnacle Clinical Research Prof. Vlad Ratziu, Professor of Hepatology, Sorbonne University and Pitié-Salpêtrière Hospital Dr. Judith Ertle, Sen...2021-06-0303 min

Dialogues on AI Digital PathologySpecial Episode (PART 3) - Conversation with KOL Hepatologists and Pharma Thought Leaders in NASHGuests Prof. Stephen Harrison (Pinnacle Clinical Research) Prof. Vlad Ratziu (Sorbonne University Pitié-Salpêtrière Hospital) Dr. Judith Ertle (Boehringer Ingelheim) Dr. Karin Conde-Knape (Novo Nordisk) Ms. Kitty Yale (Akero Therapeutics) Moderator Dr. Nikolai Naoumov (Novartis) Key Takeaways 1) The innovation and qualities that AI Digital Pathology (AI-DP) brings to drug development can be described as a disruptive technology as it expands the knowledge of NASH pathobiology, introduces standardization and reproducibility on a fully qua...2021-05-1757 min

Dialogues on AI Digital Pathology[Official Trailer] Special Episode (PART 3) - Conversation with KOL Hepatologists and Pharma Thought Leaders in NASHOur Special Episode conversation on AI Digital Pathology in NASH Drug Development continues (in Parts 3 and 4) with our guests, KOL hepatologists and Pharma Thought Leaders in NASH, as they respond to questions by Pharma companies and clinical investigators on how AI Digital Pathology (AI-DP) can augment clinical trial data and work alongside pathologists to detect granular information that could be pivotal for determining patient recruitment, staging and treatment responses. The full Part 3 podcast will be launched early next week, so click here to listen to the Trailer of Part 3! A huge Thank You...2021-05-1403 min

Surfing the MASH TsunamiS2-E15 — Wrapping Up NASH-TAG 2021Surfing the NASH Tsunami closes the book on NASH-TAG 2021 by considering highlights and major themes of the conference. The conversation focuses on the dramatic increase in disease knowledge and drug development over the past year and highlights some specific papers and ideas. A thoughtful, energetic conclusion to a meeting that left much to think about and many reasons to be excited.NASH-TAG co-director Vlad Ratziu and Global Liver Institute President/CEO Donna Cryer join the Surfers to review high points of the conference. The discussion ranges from the reasons that NASH-TAG is so special to...2021-03-1852 min

Surfing the MASH TsunamiS2 E11 — NASH-TAG Session 1 summary: Major Drugs in Development and Why Trials FailManal Abdelmalek and Ian Rowe join Roger, Louise and Donna to review the morning that Vlad Ratziu and Michael Charlton both identified as the highlight session of NASH-TAG 2021. The Friday morning session of NASH-TAG 2021 highlights advancing research for five major NASH drugs in development, explores the question why drug trials fail and wraps up with a rapid-fire session on promising data. Surfers were excited about some of the new drugs and found the presentations from Vlad Ratziu and Mary Rinella about why cirrhotic and non-cirrhotic drug trials fail to be particularly powerful and well-presented. Af...2021-03-1250 min

Surfing the MASH TsunamiS2 E10 — Before NASH-TAG, Conversations With Co-DirectorsNASH-TAG Co-directors Vlad Ratziu and Michael Charlton talk with Roger Green about the upcoming conference, after which Roger discusses the SurfingNASH coverage plan for NASH-TAG.If you listen to SurfingNASH, you already know exactly how Stephen Harrison feels about NASH-TAG and what lights him up about this year's agenda. Now, listen as two other co-directors, Vlad Ratziu and Michael Charlton, discuss how the meeting started, what makes it special and what they are looking forward to most in this year's event as they speak with Roger Green. Afterwards, Roger announces the SurfingNASH coverage p...2021-03-1140 min

Clinical Liver DiseaseManagement of nonalcoholic steatohepatitis: Pharmacotherapy - Vlad Ratziu – Article ReadingCurrent guidelines do not recommend the use of hepatic pharmacological therapy in patients with steatosis alone. Instead, patients with NASH and significant liver disease (bridging fibrosis) are good candidates for therapy. Dr. Ratzui outlines the current guidelines, best available evidence, and potential pharmacologic management of the patient with NASH.2013-07-0706 min